Background {#Sec1}
==========

According the Central Brain Tumor Registry of the US (CBTRUS), there are over 138,000 people in the US living with primary brain and central nervous system malignant tumors primary in the United States \[[@CR1]\]. The incidence of primary malignant brain tumors is expected to be over 23,000 in 2015 \[[@CR1]\]. Of these types of tumors, \>50 % \[[@CR2]--[@CR4]\] (approximately 11,500) are classified as being at high risk \[for complications\] for resection. This is mainly due to the grade of tumor and these tumors residing in or near areas of eloquence or being deep seated in nature (e.g. tumor residing in the brain stem \[also referred to as complex anatomy\]). Extent of resection (EOR) with the aim of maximal cytoreduction of the tumor is strongly correlated with outcomes (i.e. survival and function as classified under the Karnofsky performance scale) \[[@CR5]\] and the effectiveness of other treatment modalities such as radiation or chemotherapy \[[@CR6], [@CR7]\]. One of the main issues with tumors that are in or near areas of eloquence or, that are deep seated in nature, is an inability for neurosurgeons to adequately resect the tumor without causing longer term neurological complications from surgery (i.e. open resection or biopsy or CURRENT TREATMENTS). Craniotomy procedures that have been performed on high-grade gliomas in or near areas of eloquence have historically resulted in neurological complications (i.e. functional and/or cognitive deficits on a neurological basis) that are permanent in nature and result in suboptimal resection. These major complication rates range from 4.5 to 13 % in large cohorts of patients \[[@CR8]--[@CR17]\] and also result in suboptimal EOR of 78--\<95 % \[[@CR5], [@CR8], [@CR12]--[@CR14]\]^.^ Further, these acquired neurological complications resulting from surgery result in decreased median survival rates \[[@CR18]\]. While the National Comprehensive Cancer Network (NCCN) includes the use of craniotomy or biopsy \[[@CR19]\] \[referred to as CURRENT TREATMENTS moving forward\] for subtotal resection in its treatment algorithms for primary or recurrent glioblastoma (where maximal resection is not safe or feasible), it does not make evidentiary or consensus recommendations on their use \[[@CR19]\].

Recently new MRI guided laser interstitial thermal therapy (LITT) systems for ablating neurological soft-tissue have been FDA cleared and; covered and paid for by Medicare (via a new technology add on payment) in treating primary and recurrent gliomas \[[@CR20], [@CR21]\]. These technologies, have been reported on extensively in the literature, including in two systematic reviews \[[@CR22], [@CR23]\]. These technologies apply focused laser energy which a surgeon uses to ablate tissue such as tumors from the inside of the brain (using a bur or twist drill hole for brain access). Real time MRI thermometry is also used so that surrounding healthy tissue damage can be minimized. These systems allow surgeons to selectively ablate tumors and lesions in the brain that may have been previously deemed inoperable, difficult to access, or unsafe to resect based on their location in or near areas of eloquence.

In examining the use of brain LITT in the peer review literature in the subset of patients whose high grade glioma resides in or near areas of eloquence or; that are deep seated in nature, it was found that the major complication rates directly resulting from the brain LITT surgery were in the 0--6 % range; average of 2.7 % (Table [1](#Tab1){ref-type="table"}), which is lower than 4.5--13 % seen in CURRENT TREATMENTS (Table [2](#Tab2){ref-type="table"}). (Note: The analysis as found in Table [1](#Tab1){ref-type="table"} shows all types of brain LITT used in high-grade gliomas located in areas of eloquence over the years, with and without the use of MRI guidance.) As well, it has been found that physicians who are experienced in using brain LITT technology in complex anatomy experience an EOR approaching 98 % \[[@CR24]\] and that those who are treated with brain LITT experience a length of stay (LOS) that averages 3 days \[[@CR24]\]. This is in contrast to patients who are treated with open craniotomy with ICD9CM Diagnosis codes 191.0--191.8, whose LOS average 6.55 ± 1.77 days under diagnostic related groups \[DRG\] 25--27 (craniotomy with and without comorbidity/complication) \[[@CR25]\].Table 1Studies examining the use of LITT with high grade gliomas in areas of eloquenceStudyNumber patients identified with tumors in areas of eloquenceTumor typeLength of stayExtent resectionKPS (pre/post)Major complications (%)^a^Sakai \[[@CR42]\]3Denovo gliomaN/A100 %Two patients had a 90 and 100 KPS pre-surgery; other not mentioned0Reimer \[[@CR43]\]4Recurrent gliomaShorter with LITT vs. craniotomyN/AN/A0Schwarzmaier \[[@CR40]\]16rGBMShorter with LITT vs. craniotomyN/AN/A0Carpentier \[[@CR44]\]4rGBMPatients discharged the next day100 %Unchanged pre and post-surgery0Jethwa \[[@CR45]\]3GBMMedian 1 day100 %N/A0Sloan \[[@CR46]\]8rGBM3.75 ± 1.83 days (mean ± SD)78 ± 12 %Pre-surgery 85; post 830Schroeder \[[@CR47]\]2Anaplastic astrocytomaN/A92.8 % (mean) \[range 77.7--100 %\]Pre-surgery 800Mohammadi \[[@CR24]\]35rGBM = 19\
Glioma/GBM = 16Median 3 days (range 1--29 days)98.2 % (median)Pre-surgery 806Totals75(2/75 = 2.7)*KPS* Karnofsky performance scale, *rGBM* recurrent glioblastoma multiforme, *GBM* glioblastoma multiforme^a^Major complications = Neurocognitive complications extending \>3 months post surgeryTable 2Studies examining the use of craniotomy with high grade gliomas in areas of eloquenceStudyNumber patients identified with tumors in areas of eloquenceTumor typeLength of stayExtent resectionKPS (presurgery/postsurgery)Major complications^a^Sawaya \[[@CR14]\]154Metastatic disease 48 %; GBM 27 %Median 5 days37 % had \<95 % EORPost 32 % improved; 58 % no change; 9 % deterioration13 %Lacroix \[[@CR13]\]79rGBM 17 %\
GBM 83 %N/A78 %N/A9 %Jackson \[[@CR16]\]78GBMN/AMedian 96 %N/A12.8 %Kim \[[@CR17]\]200Primarily GBMN/A125/200 patients had a GTR (63 %) \[defined as ≥95 %\]; 20/200 (14 %) STR, 46/200 (23 %) partial resectionN/A11 %Sanai \[[@CR9]\]40Insular gliomas WHO Type III & IVN/A87.5 % had \<90 % EORN/A4.8 %Kuhnt \[[@CR12]\]79GBM\
rGBMN/A78.2 %N/A9 %Kreig \[[@CR11]\]47GBM; anaplastic astrocytoma, diffuse astrocytomaN/A90 % going to 80 %8.5 %Chaichana \[[@CR10]\]146GBMMedian 4 days81 ± 1.6 %N/A7.3 % overall. However this was not broken out by complications in areas of eloquenceSchucht \[[@CR8]\]67GBMN/A73 % GTR 27 % STRN/A4.5 % with persistent motor deficit*KPS* Karnofsky performance scale, *GTR* gross total resection, *STR* subtotal resection^a^Major complications = neurocognitive complications extending \>3 months post surgery

In establishing the value of a new treatment, the new option is compared to the weighted costs and outcomes of the combined existing treatments \[CURRENT TREATMENTS\] for the same patient population. In the United States cost effectiveness ratios of \<\$50,000/life year gained \[LYG\] are considered attractive \[[@CR26]\]. From an international perspective, \<30,000€ (or \$32,575 in current US dollars)/LYG \[or at \$2714/month survival gained\] is considered a good value \[[@CR27]\].

It is with these facts in mind that an analysis was undertaken to evaluate the direct costs and overall survival of treating complex high-grade gliomas utilizing either brain LITT or CURRENT TREATMENTS (per the NCCN CNS practice guidelines \[[@CR19]\]). The costs and overall survival (OS) were evaluated via a cost effectiveness analysis (including sensitivity analysis) as described below. The hypothesis being tested is that the use of brain LITT in these types of patients would be considered cost effective (i.e. of value) at a willingness to pay (WTP of \<\$32,575/LYG or incremental cost \$2714/incremental month of survival) in patients with complex brain anatomy (which included brain tumors in or near areas of eloquence or; in deep seated tumors which are difficult to access via surgery). This analysis examines this incremental cost/incremental survival benefit (termed ICER).

Methods {#Sec2}
=======

A decision tree was developed to evaluate the cost-effectiveness of using brain LITT versus CURRENT TREATMENTS (collectively craniotomy ± gliadel wafer, plus biopsy) in patients with complex anatomy. Additionally, brain LITT was compared to the separate procedures of craniotomy without gliadel wafer, craniotomy w/gliadel wafer, and biopsy only (which collectively make up CURRENT TREATMENTS) in these patients. The software program used was TreeAge Pro 2014, a decision tree/Markov modeling software program widely used in health care for evaluating cost effectiveness.

The decision tree evaluated the initial procedure and the resultant outcome (i.e. gross total resection \[GTR\]; subtotal resection \[STR\])---using probabilities as identified in the peer-reviewed literature and as found in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}. Further it was assumed that patients received adjunct care (e.g. chemotherapy, external beam radiation therapy (EBRT) where appropriate based on the EOR and; as per the NCCN guidelines \[[@CR19]\], and evidence-based recommendations \[[@CR28], [@CR29]\]. Patients were followed through the treatment decision tree until they died. Gross total resection was defined as an EOR of ≥98 % and a subtotal resection (STR) was classified as less than \<98 %. The outcome of the surgery was also evaluated based on the resultant Karnofsky performance scale (KPS). The progression free survival (PFS) of the initial procedure was based off of the EOR as found in the literature and as outlined in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} below. Progression free survival times and KPS were determinants of when/whether a second procedure was performed. Further, patients whose recurring tumor was local in nature were treated with a second surgery and follow on adjunctive treatment where appropriate, based on the clinical guidelines (e.g. ± gliadel wafer \[based on evidence from databases and the literature this occurred 10--30 % of the time\] \[[@CR30], [@CR31]\], systemic chemotherapy). Patients whose tumor was diffuse in nature were treated with either palliative care or EBRT (external beam radiation therapy) ± chemotherapy, depending upon their KPS. As well, patients whose resultant KPS was \<70 after surgery were treated with palliative care for the remainder of their lives. Thus as an example: if a primary procedure under brain LITT resulted in a GTR and the outcome was favorable (e.g. KPS \>70 post procedure) (note: the primary procedure would include adjunctive EBRT plus chemotherapy)---the PFS time as identified in the literature was used for determining a second procedure. If the tumor recurred locally, a second brain LITT procedure was performed. If the outcome of the second procedure was favorable (e.g. KPS \>70) the patient was treated with follow on therapy (e.g. chemotherapy) and then followed for the remainder of their life. The decision tree for treatment followed the clinical guidelines as found in the NCCN CNS clinical practice guidelines \[[@CR19]\]^.^ Neurocognitive complication rates as identified above were also used in the model and affected treatment options and downstream costs such as rehabilitation post procedure.Table 3Variables used in the modelNameDescriptionCommentRoot definitionLowHighPercent_GTR_NeuroblatePercent of patients with a GTR deemed to be favorable for survivalData derived from Mohammadi et al. \[[@CR24]\]0.3701Percent_open_resectionPercent of patients where open cranitomy was performed for a subtotal resectionData derived from Laws RE et al. \[[@CR48]\]0.7801Cost_blended_DRG25_26Cost of craniotomy procedure for a patient with a high grade glioma---weighted average for DRGs 25--26CRANIOTOMY and ENDOVASCULAR INTRACRANIAL PROCEDURES W CC or MCC (Nat Aver)---weighted average based on frequency of procedurs in Medicare patients for the 2012 calendar year. HCUPNet source\$22,291025,000Cost_CPT_00210National average payment amount Medicare for anesthesiaAssumes surgical procedure to last at least 8 h, 30 min\$1012.5001012.5Cost_CPT_61799Stereotactic cranial lesion---complexCost of creation of an additional stereotactic lesion (each complex lesion) above and beyond that created by CPT 61798 (assume 3 additional lesions)---each lesion @ \$325/lesion (Medicare national average payment rate for 2015\$97501406.76Cost_CPT_61510National average payment Medicare for a craniotomy to remove a brain tumorCraniotomy, trephination, for excision of a brain tumor\$222502225Cost_CPT_99144Cost moederate sedation first 30 minCost for moderate sedation of patient first 30 min\$19.30019.3Cost_CPT_99145Cost moderate sedation each additional 15 min at a cost of \$9.40 for each 15 time increment\$9.40s09.4Cost_CPT_61798National average payment amount Medicare for stereotactic radiosurgeryPaid as part of the LITT procedure along with CPT 61510 and CPT 61781\$140801408Cost_CPT_61800National average payment Medicare for headframe placement2015 national average payment rate for head frame placement used in stereotactic radiosurgery\$1650235Cost_CPT_99233National average Medicare payment for E&M inpatient---subsequent patient visits\$1050105Cost_CPT_99222National average payment Medicare E&M care first patient visit\$1380138Average_LOS_surgeryAverage length of hospital stay in days for patient having surgery in an eloquent area of the brain to remove a brain neoplasmLOS_surgery_GBM06Average_LOS_LITTAverage length of hospital stay for patient having LITT surgery for brain tumor303Average_LOS_brain_biopsyAverage lengthe of hospital days for a brain biopsy---subtotal resectionDerived from 2012 HCUPNet inpatient data on ICD9CM 01.13 (closed biopsy brain)606Local_recurrence_GBMRecurrence GBM that progresses locallyData derived from Pope WB et al. \[[@CR49]\]0.7701Cost_Routine_Home_HospiceCost for routine home hospice care per day Medicare FY 2015\$1590300Percent_palliative_carePercent of patients eligible for palliative care based on surviving \<6 monthsData derived from Park JK et al. \[[@CR50]\]0.4400.44Cost_CMG_302Case mix group 302 for non-traumatic brain injury incurred during neurosurgery procedure. Surgery results in significant motor and cognitive deficitsAssumes patient has "severe" comorbidities and inpatient rehabilitation facility (IRF) is paid at national weighted average of \$23,310 for CMG 302 Tier 1 and Tier 2 at the mix of DRG 25 (59 %) and DRG 26 (41 %) (FY 2015 rate for Medicare). Derived from Federal Register, Vol. 79; No. 151, August 6, 2014, page 45888\$23,310020,000Cost_CPT_99220Observation care facility setting---initial visit; 2015 Medicare national average paymentDervied from Medicare PPS FY 2015\$1880188Cost_CPT_99226Observation care facility setting---subsequent visit; 2015 Medicare national average paymentDervied from Medicare PPS FY 2015\$1060106Cost_CPT_97001National average payment Medicare for physical therapy initial evaluationMedicare PPS FY2015\$75.44075.44Cost_CPT_97112National average payment rate for neuromuscular rehabilitation per dayMedicare PFS FY 2015\$33.61033.61Average_LOS_IRFLength of stay inpatient rehabilitation facility post complication resulting for neurosurgery in an eloquent area of the brainAssumes and average LOS of 10 days---derived from Case Mix Group 301 for nontraumatic brain injury from surgery10010Cost_APC_0067CMS payment for APC 0067---cranial SRSCMS FY 2015 payment rate for aPC 0067 @ \$9765.40---for SRS brain\$9765.40020,000Cost_CPT_77372National average payment for Medicare for treatment of brain cancer using SRS linear acceleratorMedicare FY 2015 payment rate for SRS linear based\$106301063OS_Survival_KPS_70_or_lowerOverall median survival in months with a Karnofsky Performance Score of less than or equal to 70Derived from Simpson JR et al. \[[@CR51]\]7.807.8OS_Survival_KPS_80_or_greaterOverall median survival in months with a Karnofsky Score of 80 or greaterDerived from Lacroix et al. \[[@CR13]\]11.2011.2OS_survival_SRSMedian survival time in months for patients with SRS after failed surgeryDerived from Niranjan A, et al. \[[@CR52]\]9.0309.03Cost_CPT_77262Therapeutic radiation treatment planning---intermediateRadiation treatment planning for SRS (EBRT)---Medicare reimbursement for CY 2015\$1130113Cost_CPT_77285Therapeutic radiology simulation---intermediateCost for simulation treatment---therapeutic radiology---Medicare CY 2015 payment rate\$4280428Cost_CPT_77306Cost EBRT isodose plans for radiation therapyCost for EBRT isodose planning---Medicare CY 2015\$1460146Cost_CPT_77300Cost for dosimetry calculationsMedicare reimbursement for dosimetry calculations---CY 2015\$63063Cost_CPT_77333Cost for design and construction for treatment devices used to protect normal tissuesMedicare reimbursement CY 2015 for design and construction of treatment devices used to protect normal tissues\$53053Cost_CPT_77336Cost for medical physicists time in treatment and planningMedicare reimbursement for medical physicist CY 2015\$77077Cost_CPT_77370Cost medical physicist consultative reportMedicare payment for medical physicist consultative report\$1170117Cost_CPT_77432Cost reporting patient's care---review films, review dosimetry and chartMedicare reimbursement for reporting patient's care during EBRT---CY 2015\$4190419Cost_CPT_61517Medicare reimbursement for placement of carmustine wafer placement in patient with high grade gliomaMedicare national average reimbursement amount for placement of carmustine wafer placement in patient with a high grade glioma---2015\$94094Cost_DRG_23National average reimbursement amount for DRG 23---craniotomy with major device implantationNational average payment amount for DRG 23---craniotomy with major device implantation---chemo implant (e.g. carmustine wafer. Based on level II evidence, carmustine wafers are recommended in patients for whom craniotomy is indicated. Fadul CE et al. \[[@CR28]\]\$31,090031,090Costs_Planning_EBRTCombined physician service costs for EBRTMedicare 2015 reimbursement for planning and reporting on EBRTCost_CPT_77262 + Cost_CPT_77285 + Cost_CPT_77300 + Cost_CPT_77306 + Cost_CPT_77333 + Cost_CPT_77336 + Cost_CPT_77370 + Cost_CPT_7743201416Cost_TMZ_with_radiationCost TMZ oral therapy during period of radiation---total of 6 weeksCost of TMZ as per Medicare fee schedule J8700 = \$9.75/pill. Obtained from 2013 Ingenix HCPCS level II code national average Medicare payment amount. Therefore \$9.75 X 42 = \$409.50\$4100410Cost_TMZ_per_pillCost of TMZ per pill---HCPCS code J8700Cost of TMZ per pill based on 2013 HCPCS level II code book for J8700 @ \$9.75/pill\$9.7509.75Percent_Gliadel_waferPercent of time gliadel wafer used as adjuncitve therapy in high grade glioma post craniotomyDerived from Price et al. \[[@CR30]\]Percent_Gliadel_wafer_implantations01Percent_neuro_deficit_GliadelPercent of patients experiencing neurological deficit with Gliadel waferDerived from Bregy et al. \[[@CR37]\]0.15300Percent_major_comps_surg_plus_GliadelCombination of major complications resulting from major surgery plus Gliadel usagePercent_neuro_deficit_Gliadel + Percent_major_complications_surgery00Percent_biopsy_disch_SNF_IRFPercent of patients with biopsy procedure discharged to SNF or IRF post biopsyDerived from Malone et al. 2015 World Neursurg---24.4 % of all patients with a stereotactic biopsy discharged either to SNF or IRF0.24400Cost_SNFCost skilled nursing facility in caring for a patient post brain surgeryDerived from 2015 Medicare rates in caring for a person post brain surgery in a skilled nursing facility\$493000Table 4Distributions used in the modelTypeNameDescriptionParam 1Param 2Param 3TriangularPercent_major_complications_surgeryPercent of patients experiencing a major complication from surgergy0.0450.090.13TriangularPercent_major_complications_LITTPercent of major complications resulting from LITT procedure0.00.0270.06UniformPercent_GTR_biopsyPercentage of patients who have a GTR with biopsy0.00.45UniformPercent_major_complications_biopsyPercent of major complications resulting from stereotactic biopsy0.0310.064UniformPercent_unresectable_rGBM_surgeryPercent of recurrent GBMS that are unresectable with open craniotomy surgery0.230.38UniformPercent_open_resection_totalPercent of eloquent areas of brain where a total resection was achieveable00.23UniformOS_EOR_biopsyOverall survival in months with biopsy based on an assumed extent of resection of \<=70 %4.8512TriangularOS_EOR_STROverall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of \>=85 %9.710.912.2TriangularOS_EOR_GTROverall survival in months with Subtotal Resection biopsy or craniotomy based on an assumed extent of resection of \>=98 %11.413.114.6UniformAdded_Survival_SRSAdditional overall survival in months with use of SRS in patients who have a KPS \>=707.58.5UniformOS_recurrent_Diffuse_GBMOverall survival of recurrent diffuse GBM67NormalPFS_LITT_GTRProgession free survival using LITT---assuming GTR12.213.6NormalPFS_LITT_STRProgression free survival using LITT with subtotal resection7.47NormalPFS_biopsy_GTRProgession free survival using biopsy with GTR12.213.6NormalPFS_biopsyProgression free survival using biopsy with inadequate resection4.85.2NormalPFS_surgery_GTRProgression free survival with surgery and GTR12.213.6NormalPFS_surgery_STRProgression free survival with surgery with STR7.47NormalLOS_surgery_GBMAverage LOS and std dev for GBM procedures under DGR 26; 2012 data6.551.77UniformTiming_follow_on_chemo_TMZAmount of time in days of follow on TMZ chemotherapy180360NormalIncremental_survivalIncremental overall survival with implanting a carmustine wafer versus not3.34.467TriangularPercent_neuro_comps_0\_to_3\_mths_surgeryPercent of neurological complications (motor and cognitive lasting 0--3 months requiring rehabilitation; independent of major complications =\>4 months0.060.0680.153UniformPercent_neuro_comps_0\_to_3\_mths_LITTPercent of neurological complicaitons (motor and cognitive lasting 0--3 months requiring rehabilitation; independent of major complications =\>4 months00.02UniformPercent_Gliadel_wafer_implantationsPercent of time a Gliadel wafer implanted in a patient for treating brain cancer0.10.33

Direct societal costs used in the model were derived from 2015 Medicare national averages for surgery (including hospital in-patient and physician services rendered during the inpatient stay) and follow on care (e.g. radiation therapy, chemotherapy, rehabilitation \[for a complication\] or palliative/home hospice care). These costs can be found in Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}. Table [5](#Tab5){ref-type="table"} shows what the overall costs for an acute inpatient stay for tumor removal and; is be based on a weighted average use and cost for DRG's 25--26 (using 2012 Medicare data on the incidence of each procedure and 2015 National average reimbursement rates for Medicare) \[[@CR32]\] plus the physician services rendered for each treatment type (brain LITT, craniotomy, biopsy). Table [5](#Tab5){ref-type="table"} also shows the national average weighted costs for DRG 23 (when craniotomy with gliadel wafer placement was performed). Effectiveness was evaluated as overall survival (OS) of the patient. These values were derived from the literature and based on the outcome of the first and second (if indicated and based on the clinical guidelines) surgical procedures. Costs and OS were discounted at 3 % annually---which is the most commonly used discount rate for medical therapies \[[@CR33]\]. Costs and OS used normal distributions along with confidence intervals and standard deviations for probabilistic analysis. Cost effectiveness analysis (incremental cost of using brain LITT plus other interventions (includes such interventions such as: adjunctive therapies, treatment for complications, hospice care) over the life of the patient/LYG; termed incremental cost effectiveness ratio (ICER) moving forward) was analyzed to determine whether the incremental cost/incremental survival was under internationally accepted cost/LYG thresholds. Sensitivity threshold analysis was performed to determine which variables had the greatest effect on the ICER. Lastly, Monte Carlo simulation (expected value for 10,000 simulated trials) was also run. These analyses were performed using TreeAge Pro 2014 (TreeAge Software, Inc., Williamstown, MA). Figure [1](#Fig1){ref-type="fig"} depicts a section of the decision tree related to treatment with brain LITT for gross total resection (≥98 % tumor ablated).Table 5Costs of care based on Medicare reimbursement to the hospital and physician for brain LITT, craniotomy w/carmustine, craniotomy w/o carmustine, or biopsy inpatient procedures---tumor resectionCost itemBrain LITT\
LOS = 3Craniotomy w/carumstine wafer\
LOS = 7.5Craniotomy\
LOS = 7.5Biopsy\
LOS = 6DRG 25-26---craniotomy\$22,291--\$22,291\$22,291DRG 23---craniotomy with chemo implant--\$31,090----CPT 00210---anesthesia\$1010\$1010\$1010\$1010CPT 99144/5---physician observation of sedation\$320\$320\$320\$320CPT 61510---craniotomy--\$2225\$2225--CPT 61517--\$94----CPT 61751--\$1405CPT 61781\$235----CPT 61798\$1410----CPT 61799\$975------CPT 61800\$165--\$165CPT 99222\$138\$138\$138\$138CPT 99233 @ \$105/day\$315\$840\$840\$630Total\$26,859\$35,717\$26,824\$25,959*LOS* length of stay in days, *DRG* diagnostic related group, *CPT* current procedural terminologyFig. 1Brain LITT arm of decision tree examining costs/outcomes of patients with a gross total resection

Results and discussion {#Sec3}
======================

Table [6](#Tab6){ref-type="table"} compares the overall costs and survival in employing either brain LITT or CURRENT TREATMENTS (again which is comprised of either open resection ± gliadel wafer or biopsy) in cases where high-grade gliomas reside in or near eloquent areas of the brain or are deep seated. As can be seen in the base case, the additional costs (over the lifetime of the patient) with LITT vs. CURRENT TREATMENTS is \$7508 and the overall improved survival with brain LITT vs. CURRENT TREATMENTS is 3.07 months. More specifically, as it relates to cost effectiveness, for every month in survival gained, it would cost an additional \$2445 in using brain LITT versus CURRENT TREATMENTS. This translates into an incremental cost per LYG of \$29,340 when using brain LITT. If one examines brain LITT compared to each option separately (that is the procedures contained within CURRENT TREATMENTS) the increment costs per LYG are: \$8458/LYG compared to craniotomy (which consisted of a combination of craniotomy with and without gliadel wafer) and \$48,552/LYG when compared to biopsy (Table [7](#Tab7){ref-type="table"}). Table [8](#Tab8){ref-type="table"} shows similar findings with a Monte Carlo simulation.Table 6Base case comparing LITT versus OTHER PROCEDURE on the outcomes of costs and overall survivalTreatmentCostOverall survival in monthsBrain LITT\$89,83919.04OTHER TREATMENTS\$82,33115.97Table 7Incremental cost/LYGTherapyCostOverall survival (OS) \[months\]Incremental cost/increment month survival in using brain LITTIncremental cost/LYG using brain LITTBiopsy\$63,45812.52\$4046/mth\$48,552/LYGCraniotomy (includes ± carmustine wafer)\$87,65416.94\$795/mth\$8458/LYGOTHER TREATMENTS-combines craniotomy plus biopsy)\$82,33115.97\$2445/mth\$29,340/LYGBrain LITT\$89,83919.04N/AN/ATable 8Monte Carlo simulation (run 10,000 times) comparing LITT versus OTHER PROCEDURE on the outcomes of costs and overall survivalTreatmentCostOverall survival in monthsBrain LITT\$89,785 ± \$15,88519.12 ± 3.51OTHER TREATMENTS\$82,042 ± \$22,07015.95 ± 4.04

Sensitivity analysis performed via a tornado plot (Fig. [2](#Fig2){ref-type="fig"}) showed that with a willingness to pay (WTP) of \$2714/month of survival (same as the international threshold of \$32,572/LYG) the following variables had the greatest effect on the model: Percent local recurrence of the GBM (Fig. [3](#Fig3){ref-type="fig"})---with the higher the occurrence of local GBM recurrence (vs. diffuse recurrence) the more likely brain LITT was to be cost effective; the higher the cost of a craniotomy procedure (i.e. DRG 25/26)---the more cost effective brain LITT became (Fig. [4](#Fig4){ref-type="fig"}); the higher the likelihood (or probability) of a subtotal resection (versus GTR); the less cost effective brain LITT became (Fig. [5](#Fig5){ref-type="fig"}) and; the higher the probability of use of gliadel wafers, the less cost effective brain LITT became (Fig. [6](#Fig6){ref-type="fig"}) (Note that with Fig. [6](#Fig6){ref-type="fig"}, the higher use of gliadel wafers resulted in a negative incremental cost/negative OS (resulting in a positive ICER for brain LITT---which in reality shows that the ICER is reflective of the additional cost and additional survival with gliadel versus brain LITT). What Fig. [7](#Fig7){ref-type="fig"} further clarifies is that brain LITT dominates craniotomy plus carmustine use in that it is both less expensive and produces improved overall survival (Note: Strategies that dominate are depicted in the lower right hand corner of cost effectiveness graphs and; strategies that are dominated are shown in the upper left hand corner of the same graph). Lastly Fig. [7](#Fig7){ref-type="fig"} shows that at a WTP of \$2714/additional month of survival, the favored strategy is brain LITT (as the WTP intersects with the brain LITT data point).Fig. 2Tornado sensitivity analysis---ICER measured as incremental cost per incremental month survival: LITT versus CURRENT TREATMENTSFig. 3One way sensitivity analysis---ICER local recurrence GBMFig. 4One way sensitivity analysis---ICER DRG 25/26Fig. 5One way sensitivity analysis---ICER percent subtotal resectionFig. 6One way sensitivity analysis---ICER percent gliadel wafer useFig. 7Cost-effectiveness analysis---LITT dominance

Table [9](#Tab9){ref-type="table"} shows the likelihoods of a "good performance status (Karnofsky score ≥70) post surgery with and without GTR and; the costs and OS survival associated with each (as calculated by TreeAge 2014). As mentioned above, GTR is defined as an EOR of ≥98 % (with subtotal resection \<98 % EOR). What Table [9](#Tab9){ref-type="table"} also shows is that for the "ideal outcome" for brain cancer surgery (i.e. a GTR with good performance status): this occurs 36 % of the time in brain LITT surgery (with an OS of 22.58 months); 9 % with craniotomy without gliadel wafer (with an OS of 21.75 months) and; 8 % of the time in craniotomy w/gliadel wafer (with an OS of 25.05 months). (NOTE: Biopsy was not factored in this analysis since the result is \<98 % EOR). In other words there appears to be 4× higher likelihood of having a good functional outcome along with GTR using brain LITT than with the other options available (Fig. [8](#Fig8){ref-type="fig"}).Table 9Costs and overall survival based on good performance status (Karnofsky ≥70) and extent of resection/ablation---by procedure performed---percent likelihood of event occurringProcedureCostOverall Survival (months)% occurrenceGross total resection/ablation (≥98 % EOR) and good performance status (Karnofsky ≥70) Brain LITT\$91,35622.5836 % Craniotomy w/o carmustine wafer\$89,69821.759 % Craniotomy w/carmustine wafer\$99,01325.058 %Subtotal resection (STR)/ablation (\<98 %) and good performance status (Karnofsky ≥70) Brain LITT\$89,72117.4661 % Craniotomy w/o carmustine wafer\$86,49316.9549 % (of all OTHER treatments performed) Craniotomy w/carmustine wafer\$99,67920.2515 % (of all OTHER treatments performed) Biopsy\$62,95912.7221 % (of all OTHER treatments performed)Fig. 8Cost effectiveness analysis---Willingness to Pay

Based on current US (\<\$50,000/LYG) and International (\<30,000€/LYG or \$32,575/LYG) threshold values for value, brain LITT should be considered to be "of value" as; its incremental cost/LYG gained (compared to CURRENT TREATMENTS) of \$29,340/LYG is less than the thresholds accepted as good value \[[@CR26], [@CR27]\]. If one were to examine a comparison in resection of the tumor (i.e. brain LITT compared to craniotomy---the most reasonable side by side comparison to make), the value is significantly improved at \$8458/LYG; again an amount considered to be of good value and; well below accepted thresholds internationally and in the US. As well, compared specifically to other cancer therapies, brain LITT represents a better value in money spent in extending survival \[[@CR27], [@CR34]\]^.^ Additionally, these findings have important implications for providers, payers, and patients. For providers, the use of brain LITT may extend the overall survival in these types of patients and, at a stable or possibly a better KPS (based on reduced neurological complication rates which in turn would lower KPS scores). Secondly, for payers, this represents good value based on accepted value thresholds. For patients, it appears that OS may be improved based on improved EOR; with less of a likelihood of ending up with surgical complications---which in turn can compromise cognitive and physical functioning.

There are currently no evidence based recommendations for resecting high-grade gliomas when maximal safe resection is not feasible as per the NCCN guidelines \[[@CR19]\]. While both subtotal resection and biopsy are mentioned in the NCCN clinical practice guidelines as surgical options, they have significant limitations. Both biopsy and open resection generally result in no or suboptimal resection (\<98 %) \[[@CR5], [@CR8], [@CR12]--[@CR14]\], respectively, with a high rate of surgically related complications in the resection group (4.5--13 % \[[@CR8], [@CR10]--[@CR14]\]) when used in these types of patients. As well, patients who had perioperative complications with open resection are less likely to receive radiotherapy or chemotherapy---thus affecting their survivability \[[@CR27]\].

The ideal outcome in these types of patients is to achieve GTR without postoperative neurologic complications as; cytoreduction (EOR) without complications plays a very important role in overall survival \[[@CR12], [@CR27]\]. Recent advances in less invasive brain LITT (under real time MRI guidance) have produced promising results, with lower complication rates (Table [1](#Tab1){ref-type="table"}). What this decision model demonstrates is that by improving the EOR and lowering procedure related major complications via brain LITT, the overall costs for treating these type of patients over their remaining lives increase minimally (with the additional costs being incurred post procedure via adjunct therapies used to improve OS---based mainly on the ability of clinicians to more frequently/effectively use adjunct therapies with brain LITT). These adjunct therapies can be used due to a greater volume of tumor removal with lower complication rates \[[@CR6], [@CR7], [@CR35]\]. The main reason for this is the ability of the brain laser under MRI guidance to selectively ablate cancerous lesions in and around areas of eloquence with less perioperative complications than CURRENT TREATMENTSs. Perioperative complications (including surgically acquired motor, sensory and cognitive deficits) have been found to be an independent risk factor associated with overall survival \[[@CR35]\]. An added benefit of the use of brain LITT is a decreased length of hospital stay which in turn also reduces overall costs (i.e. lower physician related costs for inpatient care) \[[@CR20]\]. Additionally, a potential benefit of brain LITT versus open resection may be the ability of patients to ambulate more quickly, potentially reducing the incidence of venous thromboembolism (VTE), which can be high in brain cancer and whose risk is further increased post craniotomy \[[@CR36]\].

The use of gliadel wafers in high grade gliomas is controversial \[[@CR37]\] and their use appears to be practiced judiciously in the US despite being recommended by the NCCN guidelines \[[@CR19]\]. The model attempted to account for this and used ranges found in the literature and in publicly available datasets \[[@CR30], [@CR31]\].

While the incremental cost/LYG using brain LITT versus biopsy only (\$48,552/LYG) exceeds the international threshold of \$32,575/LYG, it is lower than the US threshold of \<\$50,000/LYG and thus would be considered acceptable in the US. Additionally, incremental cost effectiveness ratio (ICER) threshold values established by countries such as the UK (via NICE) for end of life therapies (with the criteria for consideration under this being: life extension of \>3 months, small patient population, and prognosis of \<24 months) may be more flexible than the threshold set of £20,000--£30,000 for all other therapies/diagnostics/interventions \[[@CR38]\]. Thus it may meet the UK threshold. More importantly however, brain LITT should be compared to CURRENT TREATMENTSS as; brain LITT would take place of the other therapeutic options (craniotomy ± gliadel and biopsy) listed under CURRENT TREATMENTS in this patient population. Lastly in this analysis, incremental cost/LYG is likely the more appropriate analysis than incremental cost/quality adjusted life year (QALY) for this condition as; mortality effects are likely to have a more significant impact relative to Quality of Life (QoL analysis); along with the fact that time and resource use are especially constrained in this condition. In these type of circumstances, analysts typically have chosen LYG versus QALY \[[@CR39]\].

As it relates to limitations of this analysis the following should be noted:

It was not possible to examine KPS as an outcome based on the small number of patients where this was evaluated. However, and as mentioned above, post-surgery KPS is reflective of neurological complications resulting from surgery. Thus in aggregate, KPS would likely have been higher in the brain LITT arm of the decision tree.

Early studies with brain LITT demonstrate a learning curve and as clinicians gain more experience, it appears that the outcomes improve \[[@CR24], [@CR40]\]. Additionally, the outcomes/data used for "CURRENT TREATMENTS (open resection or biopsy)" are well established. It is possible that as time progresses and brain LITT becomes better established (especially for use in these types of patients) that the overall outcomes would improve for brain LITT.

Complications resulting in repeat surgery from chemotherapy implants (e.g. gliadel wafer); craniotomy, brain LITT and biopsy were not evaluated for cost and their effect on overall survival. These complications resulted in approximately a 3 % repeat surgery rate and are highest in the gliadel wafer group \[[@CR29], [@CR37]\].

It was assumed based on level II evidence and in the literature reviewed that gliadel wafers were implanted in approximately 10--33 % of patients in the open resection arm of CURRENT TREATMENTS \[[@CR28], [@CR29]\]. This may not be the case in all situations. If not used in all instances, the overall costs for the open resection arm (of CURRENT TREATMENTS's performed) would be less (however to the detriment of overall survival). It was also assumed in the decision tree model that the application of a chemotherapy implant conferred a 3.3 month increment in overall survival \[[@CR29]\].

Fluorescent guided surgery using 5-ALA may not be entirely accurate in identifying complete resection and is not FDA-approved in the United States \[[@CR41]\]. Some of the studies where EOR was evaluated for craniotomy used this technology \[[@CR3], [@CR8]\]. Thus the EOR for craniotomy may have been overestimated---which in turn affected the overall survival numbers in this arm of the decision tree.

Extent of ablation (EOA) from the recent Mohammadi study was used for the brain LITT arm of the trial as a proxy for EOR \[[@CR24]\]. In this study the EOA was defined by thermal damage threshold (TDT) lines. Since there is no data in the literature regarding the EOA of thermal damage by brain LITT, it was assumed that the TDT lines defined EOR and, because of this, the 98 % figure was used for EOR in the brain LITT arm of the decision tree model for both PFS and OS. In a prior review of the literature, EOA and EOR, were considered equivalent for PFS \[[@CR24]\]. Lastly, since OS had not been followed out long enough for brain LITT, it was also assumed that the 98 % value for EOA with brain LITT assumed a similar OS trajectory as craniotomy.

Conclusions {#Sec4}
===========

The use of brain LITT under MRI guidance in complex craniotomies where high-grade gliomas reside in or near areas of eloquence (or where these types of tumors are deep seated) appears to be cost effective---providing value based on it being lower than "value" thresholds established by policy makers. The implications are that brain LITT should be considered a treatment option in these types of high-risk patients.
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